Serotonin transporter: Gene, genetic disorders, and pharmacogenetics

Molecular Interventions

Volumn 4, Issue 2, 2004, Pages 109-123

  Murphy, Dennis L ^a   Lerner, Alicja ^a   Rudnick, Gary ^b   Lesch, Klaus Peter ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL) 5 METHYLPHENYLAMINE; 2 [2 (DIMETHYLAMINOMETHYLPHENYLTHIO)] 5 FLUOROMETHYLPHENYLAMINE; 3 AMINO 4[2 (DIMETHYLAMINOMETHYLPHENYLTHIO)]BENZONITRILE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ALOSETRON; AMPHETAMINE DERIVATIVE; BENZONITRILE; CHLORAMPHETAMINE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; METHCATHINONE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; AUTISM; CHROMOSOME 17; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEPRESSION; DIAPHORESIS; DNA FLANKING REGION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; EXTRACELLULAR FLUID; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HOT FLUSH; HUMAN; HYPOMANIA; IMPULSIVENESS; INSOMNIA; IRRITABLE COLON; KNOCKOUT MOUSE; MOLECULAR EVOLUTION; MOUSE; MYDRIASIS; MYOCLONUS; NAUSEA; NONHUMAN; OBESITY; PHARMACOGENETICS; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAPID CYCLING BIPOLAR DISORDER; RESTLESSNESS; REVIEW; SEROTONINERGIC SYSTEM; SHIVERING; SIDE EFFECT; SIGNAL DETECTION; SUICIDE ATTEMPT; TREMOR; VIOLENCE;

AMINO ACID SEQUENCE; ANIMALS; BRAIN; EVOLUTION, MOLECULAR; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; NERVOUS SYSTEM DISEASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 2342629856     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.2.8     Document Type: Review

References (158)

1. Lesch, K.-P. and Murphy, D.L. Molecular genetics of transporters for norepinephrine, dopamine, and serotonin in behavioral traits and complex diseases., in Membrane Transport Diseases: Molecular Basis of Inherited Transport Defects (Broer S. and Wagner C.A. eds) (in press), 2004.
2. Androutsellis-Theotokis, A., Goldberg, N.R., Ueda, K., Beppu, T., Beckman, M.L., Das, S., Javitch, J.A., and Rudnick, G. Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters. J. Biol. Chem. 278, 12703-12709 (2003).
3. Saier, M.H., Jr. Tracing pathways of transport protein evolution. Mol. Microbiol. 48, 1145-1156 (2003).
4. Bengel, D., Murphy, D.L., Andrews, A.M., Wichems, C.H., Feltner, D., Heils, A., Mossner, R., Westphal, H., and Lesch, K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4- methylenedioxy-methamphetamine ("Ecstasy") in serotonin transporter- deficient mice. Mol. Pharmacol. 53, 649-55 (1998).
5. MacKenzie, A. and Quinn, J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc. Natl. Acad. Sci. U. S. A. 96, 15251-1525 (1999).
6. Gingrich, J.A. and Hen, R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl.) 155, 1-10 (2001).
7. Murphy, D.L., Li, Q., Engel, S., Wichems, C., Andrews, A., Lesch, K.P., and Uhl, G. Genetic perspectives on the serotonin transporter. Brain Res. Bull. 56, 487-494 (2001).
8. Sora, I., Wichems, C., Takahashi, N., Li, X.F., Zeng, Z., Revay, R., Lesch, K.P., Murphy, D.L., and Uhl, G.R. Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. U S A 95, 7699-704 (1998).
9. Sora, I., Hall, F.S., Andrews, A.M. et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. U. S. A. 98, 5300-5305 (2001).
10. Hall, F.S., Li, X.F., Sora, I., Xu, F., Caron, M., Lesch, K.P., Murphy, D.L., and Uhl, G.R. Cocaine mechanisms: Enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience 115, 153-161 (2002).
11. 2-MPTP-induced depletions in serotonin and norepinephrine. Eur. J. Pharmacol. 250, 215-221 (1993).
12. 2-MPTP): A comparative study with 2′ -CH3-MPTP and MPTP. J. Neurochem. 60, 1167-1170 (1993).
13. Schuldiner, S., Steiner-Mordoch, S., Yelin, R., Wall, S.C., and Rudnick, G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44, 1227-1231 (1993).
14. Luellen, B.A., Miller, D.B., Chisnell, A.C., Murphy, D.L., O'Callaghan, J.P., and Andrews, A.M. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine. J. Pharmacol. Exp. Ther. 307, 923-931 (2003).
15. Kilic, F. and Rudnick, G. Oligomerization of serotonin transporter and its functional consequences. Proc. Natl. Acad. Sci. U. S. A. 97, 3106-3111 (2000).
16. 306 at the extracellular end of the sixth transmembrane segment. Proc. Natl. Acad. Sci. U. S. A. 98, 10055-10060 (2001).
17. Schmid, J.A., Scholze, P., Kudlacek, O., Freissmuth, M., Singer, E.A., and Sitte, H.H. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J. Biol. Chem. 276, 3805-3810 (2001).
18. Abramson, J., Smirnova, I., Kasho, V., Verner, G., Kaback, H.R., and Iwata, S. Structure and mechanism of the lactose permease of Escherichia coli. Science 301, 610-615 (2003).
19. Huang, Y., Lemieux, M.J., Song, J., Auer, M., and Wang, D.N. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301, 616-620 (2003).
20. Pebay-Peyroula, E., Dahout-Gonzalez, C., Kahn, R., Trezeguet, V., Lauquin, G.J., and Brandolin, G. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature 426, 39-44 (2003).
21. Lesch, K.-P., Balling, U., Gross, J., Strauss, K., Wolozin, B.L., Murphy, D.L., and Riederer, P. Organization of the human serotonin transporter gene. J. Neural Transm. Gen. Sect. 95, 157-162 (1994).
22. Ramamoorthy, S., Bauman, A.L., Moore, K.R., Han, H., Yang-Feng, T, Chang, A.S., Ganapathy, V., and Blakely, R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U. S. A. 90, 2542-2546 (1993).
23. Bradley, C.C. and Blakely, R.D. Alternative splicing of the human serotonin transporter gene. J. Neurochem. 69, 1356-1367 (1997).
24. Ozsarac, N., Santha, E., and Hoffman, B.J. Alternative non-coding exons support serotonin transporter mRNA expression in the brain and gut. J. Neurochem. 82, 336-344 (2002).
25. Flattem, N.L. and Blakely, R.D. Modified structure of the human serotonin transporter promoter. Mol. Psychiatry 5, 110-115 (2000).
26. Mortensen, O.V., Thomassen, M., Larsen, M.B., Whittemore, S.R., and Wilborg, O. Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res. Mol. Brain Res. 68, 141-148 (1999).
27. Lesch, K.P., Jatzke, S., Meyer, J., Stober, G., Okladnova, O., Mossner, R., and Riederer, P. Mosaicism for a serotonin transporter gene promoter-associated deletion: Decreased recombination in depression. J. Neural Transm. 106, 1223-1230 (1999).
28. Battersby, S., Ogilvie, A.D., Blackwood, D.H., Shen, S., Muqit, M.M., Muir, W.J., Teague, P., Goodwin, G.M., and Harmar, A.J. Presence of multiple functional polyadenylation signals and a single nucleotice polymorphism in the 3′ untranslated region of the human serotonin transporter gene. J. Neurochem. 72, 1384-1388 (1999).
29. Lesch, K.P., Wolozin, B.L., Estler, H.C., Murphy, D.L., and Riederer, P. Isolation of a cDNA encoding the human brain serotonin transporter. J. Neural Transm. Gen. Sect. 91, 67-72 (1993).
30. Lesch, K.P., Meyer, J., Glatz, K. et al. The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: Alternative biallelic variation in rhesus monkeys. J. Neural Transm. 104, 1259-1266 (1997).
31. Bengel, D., Johren, O., Andrews, A.M., Heils, A., Mossner, R., Sanvitto, G.L., Saavedra, J.M., Lesch, K.P., and Murphy, D.L. Cellular localization and expression of the serotonin transporter in mouse brain. Brain Res. 778, 338-345 (1997).
32. Heils, A., Wichems, C., Mossner, R., Petri, S., Glatz, K., Bengel, D., Murphy, D.L., and Lesch, K.P. Functional characterization of the murine serotonin transporter gene promoter in serotonergic raphe neurons. J. Neurochem. 70, 932-939 (1998).
33. Sakai, K., Hasegawa, C., Okura, M., Morikawa, O., Ueyama, T., Shirai, Y., Sakai, N., and Saito, N. Novel variants of murine serotonin transporter mRNA and the promoter activity of its upstream site. Neurosci. Lett. 342, 175-178 (2003).
34. Lesch, K.-P. and Moessner, R. Genetically driven variation in serotonin uptake: Is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol. Psychiatry 44, 179-192 (1998).
35. Heils, A., Teufel, A., Petri, S., Seemann, M., Bengel, D., Balling, U., Riederer, P., and Lesch, K.P. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J. Neural Transm. Gen. Sect. 102, 247-254 (1995).
36. Delbruck, S.J., Wendel, B., Grunewald, I., Sander, T., Morris-Rosendahl, D., Crocq, M.A., Berrettini, W.H., and Hoehe, M.R. A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet. Cell Genet. 79, 214-220 (1997).
37. Lesch K.-P., Bengel D., Heils A. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531 (1996).
38. Gelernter, J., Kranzler, H., and Cubells, J.F. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum. Genet. 101, 243-246 (1997).
39. Greenberg, B.D., Tolliver, T.J., Huang, S.J., Li, Q., Bengel, D., and Murphy, D.L. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets, Am. J. Med. Genet. 88, 83-87 (1999).
40. Little, K.Y., Mclaughlin, D.P., Zhang, L. et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am. J. Psychiatry 155, 207-213 (1998).
41. Hanna, G.L., Himle, J.A., Curtis, G.C., Koram, D.Q., Veenstra-VanderWeele, J., Leventhal, B.L., and Cook, E.H., Jr. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 18, 102-111 (1998).
42. Whale, R., Quested, D.J., Laver, D., Harrison, P.J., and Cowen, P.J. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology (Berl.) 150, 120-122 (2000).
43. Reist, C., Mazzanti, C., Vu, R., Tran, D., and Goldman, D. Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. Am. J. Med. Genet. 105, 363-368 (2001).
44. Eichhammer, P., Langguth, B., Wiegand, R., Kharraz, A., Frick, U., and Hajak, G. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology (Berl.) 166, 294-297 (2003).
45. Neumeister A., Konstantindis A., Stastny J. et al. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch. Gen. Psychiatry 59, 613-620 (2002).
46. Collier, D.A., Arranz, M.J., Sham, P. et al. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 7, 1675-1679 (1996).
47. Fiskerstrand, C.E., Lovejoy, E.A., and Quinn, J.P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 458, 171-174 (1999).
48. Lovejoy, E.A., Scott, A.C., Fiskerstrand, C.E., Bubb, V.J., and Quinn, J.P. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur. J. Neurosci. 17, 417-420 (2003).
49. Pugliese, A., Zeller, M., Fernandez, A., Jr. et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15, 293-7 (1997).
50. Vafiadis, P., Bennett, S.T., Todd, J.A., Nadeau, J., Grabs, R., Goodyer, C.G., Wickramasinghe, S., Colle, E., and Polychronakos, C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 15, 289-292 (1997).
51. Duan, J., Sanders, A.R., Molen, J.E., Martinolich, L., Mowry, B.J., Levinson, D.F., Crowe, R.R., Silverman, J.M., and Gejman, P.V. Polymorphisms in the 5′-untranslated region of the human serotonin receptor 1B (HTR1B) gene affect gene expression. Mol. Psychiatry 8, 901-910 (2003).
52. Kim, S.J., Cox, N., Courchesne, R. et al. Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder. Mol. Psychiatry 7, 278-288 (2002).
53. Greenwood, T.A., Alexander, M., Keck, P.E., McElroy, S., Sadovnick, A.D., Remick, R.A., Shaw, S.H., and Kelsoe, J.R. Segmental linkage disequilibrium within the dopamine transporter gene. Mol. Psychiatry 7, 165-173 (2002).
54. Glatt, C.E., DeYoung, J.A., Delgado, S., Service, S.K., Giacomini, K.M., Edwards, R.H., Risch, N., and Freimer, N.B. Screening a large reference sample to identify very low frequency sequence variants: Comparisons between two genes. Nat. Genet 27, 435-438 (2001).
55. Ozaki, N., Goldman, D., Kaye, W.H., Plotnicov, K., Greenberg, B.D., Lappalainen, J., Rudnick, G., and Murphy, D.L. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol. Psychiatry 8, 933-936 (2003).
56. Kilic, F., Murphy, D.L., and Rudnick, G. A human serotonin transporter mutation causes constitutive activation of transport activity. Mol. Pharmacol 64, 440-446 (2003).
57. Torres, G.E. and Caron, M.G. Center stage for the serotonin transporter: a gain-of-function polymorphism in persons with obsessive-compulsive disorder. Mol. Pharmacol. 64, 196-198 (2003).
58. Di Bella, D., Catalano, M., Balling, U., Smeraldi, E., and Lesch, K.P. Systematic screening for mutations in the coding region of the human serotonin transporter (5-HTT) gene using PCR and DGGE. Am. J. Med. Genet. 67, 541-545 (1996).
59. Hoffman, B.J., Hansson, S.R., Mezey, E., and Palkovits, M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front. Neuroendocrinol. 19, 187-231 (1998).
60. Hansson, S.R., Mezey, E., and Hoffman, B.J. Serotonin transporter messenger RNA in the developing rat brain: Early expression in serotonergic neurons and transient expression in non-serotonergic neurons. Neuroscience 83, 1185-1201 (1998).
61. 11C]-AFM. J. Cereb. Blood Flow Metab. 22, 1377-1398 (2002).
62. 11C]-labeled 2-(phenylthio)araalkylamines. J. Med. Chem. 43, 3103-3110 (2000).
63. 11C]-DASB binding to the human serotonin transporter: Modeling strategies. J. Cereb. Blood Flow Metab. 21, 1342-1353 (2001).
64. 11C]-DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 23, 1096-1112 (2003).
65. 11Cl-DASB. Eur. J. Nucl. Med. 27, 1719-1722 (2000).
66. 3H]-paroxetine. Neuroscience 27, 473-496 (1988).
67. 3H]-paroxetine binding, a marker of serotonin uptake sites. Biol. Psychiatry 24, 299-309 (1988).
68. 11C]-DASB PET imaging study. Am. J. Psychiatry 158, 1843-1849 (2001).
69. Li, Q., Ma L., Innis, R.B., Seneca, N., Ichise, M., Huang, H., Laruelle, M., and Murphy, D.L. Pharmacologic and genetic characterization of two selective serotonin transporter ligands: 2-[2-(dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine, (AFM) and 3-amino-4[2-(dimethyl-aminomethylphenylthio)] benzonitrile, (DASB). J. Pharmacol. Exp. Ther. 308, 481-486 (2004).
70. Montanez, S., Owens, W.A., Gould, G.G., Murphy, D.L., and Daws, L.C. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J. Neurochem. 86, 210-219 (2003).
71. Mynett-Johnson, L., Kealey, C., Claffey, E., Curtis, D., Bouchier-Hayes, L., Powell, C., and McKeon, P. Multimarker haplotypes within the serotonin transporter gene suggest evidence of an association with bipolar disorder. Am. J. Med. Genet. 96, 845-849 (2000).
72. Conroy, J., Meally, E., Kearney, G., Fitzgerald, M., Gill, M., and Gallagher, L. Serotonin transporter gene and autism: A haplotype analysis in an Irish autistic population. Mol. Psychiatry (2004). Jan 6 [Epub ahead of print].
73. Weese-Mayer, D.E., Zhou, L., Berry-Kravis, E.M., Maher, B.S., Silvestri J.M., and Marazita, M.L. Association of the serotonin transporter gene with sudden infant death syndrome: A haplotype analysis. Am. J. Med. Genet. 122A, 238-245 (2003).
74. Anguelova, M., Benkelfat, C., and Turecki, G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol. Psychiatry 8, 574-591 (2003).
75. Hahn, M.K. and Blakely, R.D. Monoamine transporter gene structure an polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J. 2, 217-235 (2002).
76. Blakely, R.D. Physiological genomics of antidepressant targets: Keeping the periphery in mind. J. Neurosci. 21, 8319-8323 (2001).
77. LaSalle V.H., Cromer K.R., Nelson K.N., Kazuba D., Justement L. and Murphy D.L. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals wiuth obsessive-compulsive disorder. Depression and Anxiety (in press).
78. Anguelova, M., Benkelfat, C., and Turecki, G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol. Psychiatry 8, 646-653 (2003).
79. Caspi, A., Sugden, K., Moffitt, T.E. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389 (2003). Epidemiology-based report of hSERT x environment interaction in >800 individuals.
80. Hariri, A.R., Mattay, V.S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M.F., and Weinberger, D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 297, 400-403 (2002).
81. Tjurmina, O.A., Armando, I., Saavedra, J.M., Goldstein, D.S., and Murphy, D.L. Exaggerated adrenomedullary response to immobilization in mice with a targeted disruption of the serotonin transporter gene. Endocrinology 143, 4520-4526 (2002).
82. Murphy, D.L., Uhl, G.R., Holmes, A., Ren-Patterson, R., Hall, F.S., Sora, I., Detera-Wadleigh, S., and Lesch K.P. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav. 2, 350-364 (2003).
83. Eddahibi S., Humbert M., Fadel E. et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108, 1141-1150 (2001).
84. Abenhaim L., Moride Y., Brenot F. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335, 609-616 (1996).
85. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., and Schaff, H.V. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997).
86. Eddahibi, S., Fabre, V., Boni, C., Martres, M.P., Raffestin, B., Hamon, M., and Adnot, S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ. Res. 84, 329-336 (1999).
87. Eddahibi, S., Hanoun, N., Lanfumey, L., Lesch, K.P., Raffestin, B., Hamon, M., and Adnot, S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105, 1555-1562 (2000).
88. Eddahibi, S., Chaouat, A., Morrell, N. et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108, 1839-1844 (2003).
89. Rabinovitch, M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J. Clin. Invest. 108, 1109-1111 (2001).
90. Fumeron, F., Betoulle, D., Nicaud, V., Evans, A., Kee, F., Ruidavets, J.B., Arveiler, D., Luc, G., and Cambien, F. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de I'lnfarctus du Myocarde (ECTIM). Circulation 105, 2943-2945 (2002).
91. Coto, E., Reguero, J.R., Alvarez, V. et al. 5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin. Sci. (Lond.) 104, 241-245 (2003).
92. Sauer, W.H., Berlin, J.A., and Kimmel, S.E. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 108, 32-36 (2003).
93. Comings, D.E., MacMurray, J.P., Gonzalez, N., Ferry, L., and Peters, W.R. Association of the serotonin transporter gene with serum cholesterol levels and heart disease. Mol. Genet. Metab. 67, 248-253 (1999).
94. Williams, R.B., Marchuk, D.A., Gadde, K.M. et al. Central nervous system serotonin function and cardiovascular responses to stress. Psychosom. Med. 63, 300-305 (2001).
95. McCaffery, J.M., Bleil, M., Pogue-Geile, M.F., Ferrell, R.E., and Manuck, S.B. Allelic variation in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cardiovascular reactivity in young adult male and female twins of European-American descent. Psychosom. Med. 65, 721-728 (2003).
96. Gershon, M.D. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol. Ther. 13 Suppl 2, 15-30 (1999).
97. Pata, C., Erdal, M.E., Derici, E., Yazar, A., Kanik, A., and Ulu, O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am. J. Gastroenterol. 97, 1780-1784 (2002).
98. Camilleri, M., Atanasova, E., Carlson, P.J., Ahmad, U., Kim, H.J., Viramontes, B.E., McKinzie, S., and Urrutia, R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123, 425-432 (2002).
99. Chen, J.J., Li, Z., Pan, H., Murphy, D.L., Tamir, H., Koepsell, H., and Gershon, M.D. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21, 6348-6361. (2001). Mouse model with IBS features.
100. Liu, M.T., Rayport, S., Jiang, Y., Murphy, D.L., and Gershon M.D. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G1398-G1411 (2002).
101. Murphy, V.E., Mynett-Johnson, L.A., Claffey, E., Bergin, P., McAuliffe, M., Kealey, C., and McKeon, P. Search for bipolar disorder susceptibility loci: The application of a modified genome scan concentrating on gene-rich regions. Am. J. Med. Genet. 96, 728-732 (2000).
102. Liu, J., Juo, S.H., Dewan, A. et al. Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Mol. Psychiatry 8, 333-342 (2003).
103. Dick, D.M., Foroud, T., Flury, L. et al. Genomewide linkage analyses of bipolar disorder: A new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am. J. Hum. Genet. 73, 107-114 (2003).
104. Kent, L., Doerry, U., Hardy, E. et al. Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit hyperactivity disorder (ADHD): Analysis and pooled analysis. Mol. Psychiatry 7, 908-912 (2002).
105. Fisher, S.E., Francks, C., McCracken, J.T. et al. A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am. J. Hum. Genet. 70, 1183-1196 (2002).
106. Zhang, H., Leckman, J.F., Pauls, D.L., Tsai, C.P., Kidd, K.K., and Campos, M.R. Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. Am. J. Hum. Genet. 70, 896-904 (2002).
107. Yonan A.L., Alarcon M., Cheng R. et al. A genomewide screen of 345 families for autism-susceptibility loci. Am. J. Hum. Genet. 73, 886-897 (2003).
108. IMGSAC. A genomewide screen for autism: Strong evidence for linkage to chromosomes 2q, 7q, and 16p. Am. J. Hum. Genet. 69, 570-581 (2001).
109. Mazzanti, C.M., Lappalainen, J., Long, J.C., Bengel, D., Naukkarinen, H., Eggert, M., Virkkunen, M., Linnoila, M., and Goldman, D. Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Arch. Gen. Psychiatry 55, 936-940 (1998).
110. Garpenstrand, H., Annas, P., Ekblom, J., Oreland, L., and Fredrikson, M. Human fear conditioning is related to dopaminergic and serotonergic biological markers. Behav. Neurosci. 115, 358-364 (2001).
111. Schmidt, N.B., Storey, J., Greenberg, B.D., Santiago, H.T., Li, Q., and Murphy, D.L. Evaluating gene x psychological risk factor effects in the pathogenesis of anxiety: A new model approach. J. Abnorm. Psychol. 109, 308-320 (2000).
112. Sora, I., Li, X.F., Funada, M., Kinsey, S., and Uhl, G.R. Visceral chemical nociception in mice lacking mu-opioid receptors: Effects of morphine, SNC80 and U-50,488. Eur. J. Pharmacol. 366, R3-R5 (1999).
113. Wisor, J.P., Wurts, S.W., Hall, F.S., Lesch, K.P., Murphy, D.L., Uhl, G.R., and Edgar, D.M. Altered rapid eye movement sleep timing in serotonin transporter knockout mice. Neuroreport 14, 233-238 (2003).
114. Holmes, A., Yang, R.J., Murphy, D.L., and Crawley J.N. Age-related obesity in 5-HT transporter deficient mice. Abstract 4071. Society for Neuroscience, New Orleans, LA (2003).
115. Vogel, C., Mossner, R., Gerlach, M., Heinemann, T., Murphy, D.L., Riederer, P., Lesch, K.P., and Sommer, C. Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J. Neurosci. 23, 708-715 (2003).
116. Holmes, A., Murphy, D.L., and Crawley, J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: Parallels with human anxiety and depression. Biol. Psychiatry 54, 953-959 (2003).
117. Holmes, A., Yang, R.J., Lesch, K.-P., Crawley, J.N., and Murphy, D.L. Mice lacking the serotonin transporter exhibit 5-HT1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28, 2077-2088 (2003).
118. Jacob, C.P., Strobel, A., Holhenberger, K., Ringel, T., Gutknecht, L., Reif, A., Brocke, B., and Lesch, K.-P. Association between allelic variation of serotonin transporter function and neuroticism in anxious cluster personality disorders. Am. J. Psychiatry 161, 569-522 (2004).
119. Yavarone, M.S., Shuey, D.L., Tamir, H., Sadler, T.W., and Lauder, J.M. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47, 573-584 (1993).
120. Persico, A.M., Mengual, E., Moessner, R. et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J. Neurosci. 21, 6862-6873 (2001).
121. Manji, H.K., Quiroz, J.A., Sporn, J., Payne, J.L., Denicoff, K., Gray, N.A., Zarate, C.A., Jr., and Charney, D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53, 707-742 (2003).
122. McDougle, C.J., Epperson, C.N., Price, L.H., and Gelernter, J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive-compulsive disorder. Mol. Psychiatry 3, 270-273 (1998).
123. Blier, P. and de Montigny, C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol. Psychiatry 44, 313-323 (1998).
124. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
125. Steimer, W., Muller, B., Leucht, S., and Kissling, W. Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy. Clin. Chim. Acta 308, 33-41 (2001).
126. Dahl, M.L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., and Sjoqvist, F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274, 516-520 (1995).
127. Serretti, A., Lilli, R., and Smeraldi, E. Pharmacogenetics in affective disorders. Eur. J. Pharmacol. 438, 117-128 (2002).
128. Lesch, K.-P. and Gutknecht, L. Pharmacogenetics of the serotonin transporter. Prog. Neuropsychopharmacol. Biol. Psychiatry (in press).
129. Kim. D.K., Lim. S.W., Lee. S., Sohn. S.E., Kim. S., Hahn. C.G.. and Carroll. B.J. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11, 215-219 (2000).
130. Yoshida K., Ito K., Takahashi H. et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluovoxamine in Japanese depressed patient. Prog. Neuropsychopharmacol. Biol. Psychiatry 158, 383-386 (2002).
131. Nakamura, T., Matsushita, S., Nishiguchi, N., Kimura, M., Yoshino, A., and Higuchi S. Association of a polymorphism of the 5HT2A receptor gene promoter region with alcohol dependence. Mol. Psychiatry 4, 85-88 (1999).
132. Nakamura, K., Goto, F., Ray, W.A., McAllister, C.B., Jacqz, E., Wilkinson, G.R., and Branch, R.A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38, 402-408 (1985).
133. Billett, E.A., Richter, M.A., King, N., Heils, A., Lesch, K.-P., and Kennedy, J.L. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol. Psychiatry 2, 40340-6 (1997).
134. Di Bella, D., Erzegovesi, S., Cavallini, M.C., and Bellodi, L. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J. 2, 176-181 (2002).
135. Bengel, D., Greenberg, B.D., Corá-Locatelli, G., Altemus, M., Heils, A., Li, Q., and Murphy, D.L. Association of the serotonin transporter promoter regulatory region and obsessive-compulsive disorder. Mol. Psychiatry 4, 463-466 (1999).
136. Holmes, A., Yang, R.J., Murphy, D.L., and Crawley, J.N. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27, 914-923 (2002).
137. Perlis, R.H., Mischoulon, D., Smoller, J.W., Wan, Y.J., Lamon-Fava, S., Lin, K.M., Rosenbaum, J.F., and Fava, M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54, 879-883 (2003).
138. Mundo, E., Walker, M., Cate, T., Macciardi, F., and Kennedy, J.L. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: Preliminary findings. Arch. Gen. Psychiatry 58, 539-544 (2001).
139. Rousseva A., Henry C., van den Bulke D. et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 3, 101-104 (2003).
140. Bunney, W.E., Jr., Goodwin, F.K., and Murphy, D.L. The "switch process" in manic-depressive illness. 3. Theoretical implications. Arch. Gen. Psychiatry 27, 312-317 (1972).
141. Murphy, D.L., Brodie, H.K., Goodwin, F.K., and Bunney, W.E., Jr. Regular induction of hypomania by L-clopa in "bipolar" manic-depressive patients. Nature 229, 135-136 (1971).
142. Kamali, M., Oquendo, M.A., and Mann, J.J. Understanding the neurobiology of suicidal behavior. Depress. Anxiety 14, 164-176 (2001).
143. Murphy, G.M., Jr., Kremer, C., Rodrigues, H.E., and Schatzberg, A.F. Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry 160, 1830-1835 (2003).
144. Insel, T.R., Roy, B.F., Cohen, R.M., and Murphy, D.L. Possible development of the serotonin syndrome in man. Am. J. Psychiatry 139, 954-955 (1982).
145. Murphy, D.L. The behavioral toxicity of monoamine oxidase-inhibiting antidepressants. Adv. Pharmacol. Chemother. 14, 71-105 (1977).
146. Wooltorton, E. Paroxetine (Paxil®, Seroxat®): Increased risk of suicide in pediatric patients. CMA J. 169, 446 (2003).
147. Narita, N., Narita, M., Takashima, S., Nakayama, M., Nagai, T., and Olkado, N. Serotonin transporter gene variation is a risk factor for sudden infant death syndrome in the Japanese population. Pediatrics 107, 690-692 (2001).
148. Klauck, S.M., Poustka, F., Benner, A., Lesch, K.P., and Poustka, A. Serotonin transporter (5-HTT) gene variants associated with autism? Hum. Mol. Genet. 6, 2233-2238 (1997).
149. Yirmiya, N., Pilowsky, T., Nemanov, L., Arbelle, S., Feinsilver, T., Fried, I., and Ebstein, R.P. Evidence for an association with the serotonin transporter promoter region polymorphism and autism. Am. J. Med. Genet. 105, 381-386 (2001).
150. Cook, E.H., Jr., Courchesne, R., Lord, C., Cox, N.J., Yan, S., Lincoln A., Haas R., Courchesne, E., and Leventhal, B.L. Evidence of linkage between the serotonin transporter and autistic behavior. Mol. Psychiatry 2, 247-250 (1997).
151. Shannon, J.R., Flattem, N.L., Jordan, J., Jacob, G., Black, B.K., Biaggioni, I., Blakely, R.D., and Robertson, D. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342, 541-549 (2000).
152. Hahn, M.K., Robertson, D., and Blakely, R.D. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J. Neurosci. 23, 4470-4478 (2003).
153. Paczkowski, F.A., Bonisch, H., and Bryan-Lluka, L.J. Pharmacological properties of the naturally occurring Ala457Pro variant of the human norepinephrine transporter. Pharmacogenetics 12, 165-173 (2002).
154. Polymeropoulos, M.H., Lavedan, C., Leroy, E. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
155. Goate, A., Chartier-Harlin, M.C., Mullan, M. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
156. Wang, L., Fan, C., Topol, S.E., Topol, E.J., and Wang, Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 302, 1578-1581 (2003).
157. Cargill M., Altshuler D., Ireland J. et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22, 231-238 (1999).
158. Lesch, K.P., Gross, J., Franzek, E., Wolozin, B.L., Riederer, P., and Murphy, D.L. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol. Psychiatry 37, 215-223 (1995).